

Sidharth Mehan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197843/publications.pdf>

Version: 2024-02-01

67
papers

1,354
citations

430874

18
h-index

414414

32
g-index

72
all docs

72
docs citations

72
times ranked

1072
citing authors

#	ARTICLE	IF	CITATIONS
1	Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine – a PDE1 inhibitor. <i>European Journal of Pharmacology</i> , 2009, 620, 49-56.	3.5	151
2	JNK: A Stress-Activated Protein Kinase Therapeutic Strategies and Involvement in Alzheimer’s and Various Neurodegenerative Abnormalities. <i>Journal of Molecular Neuroscience</i> , 2011, 43, 376-390.	2.3	136
3	Understanding multifactorial architecture of Parkinson’s disease: pathophysiology to management. <i>Neurological Sciences</i> , 2019, 40, 13-23.	1.9	67
4	Targeting PI3K-AKT/mTOR signaling in the prevention of autism. <i>Neurochemistry International</i> , 2021, 147, 105067.	3.8	49
5	Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence. <i>Toxicology Reports</i> , 2019, 6, 1164-1175.	3.3	48
6	Neuroprotective effect of solanesol against 3-nitropropionic acid-induced Huntington’s disease-like behavioral, biochemical, and cellular alterations: Restoration of coenzyme-Q10-mediated mitochondrial dysfunction. <i>Indian Journal of Pharmacology</i> , 2018, 50, 309.	0.7	44
7	Neuroprotective Effect of \pm -Mangostin in Ameliorating Propionic Acid-Induced Experimental Model of Autism in Wistar Rats. <i>Brain Sciences</i> , 2021, 11, 288.	2.3	40
8	Adenyl cyclase activator forskolin protects against Huntington’s disease-like neurodegenerative disorders. <i>Neural Regeneration Research</i> , 2017, 12, 290.	3.0	39
9	Adenylate cyclase activator forskolin alleviates intracerebroventricular propionic acid-induced mitochondrial dysfunction of autistic rats. <i>Neural Regeneration Research</i> , 2020, 15, 1140.	3.0	38
10	Neuroprotective potential of solanesol in a combined model of intracerebral and intraventricular hemorrhage in rats. <i>IBRO Reports</i> , 2020, 8, 101-114.	0.3	36
11	Nrf2/HO-1 Signaling Activator Acetyl-11-keto-beta Boswellic Acid (AKBA)-Mediated Neuroprotection in Methyl Mercury-Induced Experimental Model of ALS. <i>Neurochemical Research</i> , 2021, 46, 2867-2884.	3.3	34
12	Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain. <i>Metabolic Brain Disease</i> , 2021, 36, 911-925.	2.9	33
13	Smo-Shh signaling activator purmorphamine ameliorates neurobehavioral, molecular, and morphological alterations in an intracerebroventricular propionic acid-induced experimental model of autism. <i>Human and Experimental Toxicology</i> , 2021, 40, 1880-1898.	2.2	28
14	Experimental evidence for the potential of lycopene in the management of scopolamine induced amnesia. <i>RSC Advances</i> , 2015, 5, 72881-72892.	3.6	27
15	Neuroprotection by solanesol against ethidium bromide-induced multiple sclerosis-like neurobehavioral, molecular, and neurochemical alterations in experimental rats. <i>Phytomedicine Plus</i> , 2021, 1, 100051.	2.0	26
16	Guggulsterone Mediated JAK/STAT and PPAR-Gamma Modulation Prevents Neurobehavioral and Neurochemical Abnormalities in Propionic Acid-Induced Experimental Model of Autism. <i>Molecules</i> , 2022, 27, 889.	3.8	26
17	Protective effects of apigenin on methylmercury-induced behavioral/neurochemical abnormalities and neurotoxicity in rats. <i>Human and Experimental Toxicology</i> , 2022, 41, 096032712210842.	2.2	26
18	Design, synthesis and neuropharmacological evaluation of new 2,4-disubstituted-1,5-benzodiazepines as CNS active agents. <i>Bioorganic Chemistry</i> , 2020, 101, 104010.	4.1	24

#	ARTICLE	IF	CITATIONS
19	Understanding Abnormal SMO-SHH Signaling in Autism Spectrum Disorder: Potential Drug Target and Therapeutic Goals. Cellular and Molecular Neurobiology, 2022, 42, 931-953.	3.3	20
20	Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions. Neurological Sciences, 2021, 42, 3145-3166.	1.9	20
21	Targeting Nrf2/HO-1 anti-oxidant signaling pathway in the progression of multiple sclerosis and influences on neurological dysfunctions. Brain Disorders, 2021, 3, 100019.	1.7	20
22	Connection between JAK/STAT and PPAR γ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain. Current Molecular Pharmacology, 2021, 14, 823-837.	1.5	18
23	Neuroprotective Potential of Adenyl Cyclase/cAMP/CREB and Mitochondrial CoQ10 Activator in Amyotrophic Lateral Sclerosis Rats. Current Bioactive Compounds, 2021, 17, .	0.5	18
24	Effect of alpha-mangostin in the prevention of behavioural and neurochemical defects in methylmercury-induced neurotoxicity in experimental rats. Toxicology Reports, 2022, 9, 977-998.	3.3	17
25	Activation of IGF-1/GLP-1 Signalling via 4-Hydroxyisoleucine Prevents Motor Neuron Impairments in Experimental ALS-Rats Exposed to Methylmercury-Induced Neurotoxicity. Molecules, 2022, 27, 3878.	3.8	17
26	Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings. Journal of Alzheimer's Disease Reports, 2019, 3, 179-218.	2.2	16
27	Inhibition of c-JNK/p38MAPK signaling pathway by Apigenin prevents neurobehavioral and neurochemical defects in ethidium bromide-induced experimental model of multiple sclerosis in rats: Evidence from CSF, blood plasma and brain samples. Phytomedicine Plus, 2021, 1, 100139.	2.0	16
28	Smo-Shh Agonist Purmorphamine Prevents Neurobehavioral and Neurochemical Defects in 8-OH-DPAT-Induced Experimental Model of Obsessive-Compulsive Disorder. Brain Sciences, 2022, 12, 342.	2.3	16
29	Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-28.	4.0	16
30	Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 1845-1868.	1.2	15
31	Neuroprotective efficacy of 4-Hydroxyisoleucine in experimentally induced intracerebral hemorrhage. Saudi Journal of Biological Sciences, 2021, 28, 6417-6431.	3.8	15
32	Understanding Abnormal c-JNK/p38MAPK Signaling Overactivation Involved in the Progression of Multiple Sclerosis: Possible Therapeutic Targets and Impact on Neurodegenerative Diseases. Neurotoxicity Research, 2021, 39, 1630-1650.	2.7	15
33	Role of JAK-STAT and PPAR-Gamma Signalling Modulators in the Prevention of Autism and Neurological Dysfunctions. Molecular Neurobiology, 2022, 59, 3888-3912.	4.0	15
34	PI3K/AKT/mTOR signalling inhibitor chrysophanol ameliorates neurobehavioural and neurochemical defects in propionic acid-induced experimental model of autism in adult rats. Metabolic Brain Disease, 2022, 37, 1909-1929.	2.9	15
35	Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings. Current Drug Discovery Technologies, 2021, 18, 31-46.	1.2	14
36	Investigation of Low Dose Cabazitaxel Potential as Microtubule Stabilizer in Experimental Model of Alzheimer's Disease: Restoring Neuronal Cytoskeleton. Current Alzheimer Research, 2020, 17, 601-615.	1.4	14

#	ARTICLE	IF	CITATIONS
37	Involvement of adenylate cyclase/cAMP/CREB and SOX9/MITF in melanogenesis to prevent vitiligo. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1401-1409.	3.1	13
38	Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders. <i>Current Molecular Medicine</i> , 2021, 21, 630-644.	1.3	13
39	Inhibition of extracellular regulated kinase (ERK)-1/2 signaling pathway in the prevention of ALS: Target inhibitors and influences on neurological dysfunctions. <i>European Journal of Cell Biology</i> , 2021, 100, 151179.	3.6	12
40	Polyphenol Ellagic Acid-Targeting To Brain: A Hidden Treasure. <i>International Journal of Neurology Research</i> , 2015, 1, 141-152.	0.2	12
41	<i>Boswellia serrata-frankincense</i> (A Jesus Gifted Herb); An Updated Pharmacological Profile. <i>Pharmacologia</i> , 2013, 4, 457-463.	0.3	12
42	Targeting Abnormal PI3K/AKT/mTOR Signaling in Intracerebral Hemorrhage: A Systematic Review on Potential Drug Targets and Influences of Signaling Modulators on Other Neurological Disorders. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2022, 17, 174-191.	0.8	11
43	Neuroprotective Effect of Chrysophanol as a PI3K/AKT/mTOR Signaling Inhibitor in an Experimental Model of Autologous Blood-induced Intracerebral Hemorrhage. <i>Current Medical Science</i> , 2022, 42, 249-266.	1.8	11
44	Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2022, Volume 12, 31-59.	1.3	11
45	Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 417-429.	1.4	10
46	Exploring Molecular Approaches in Amyotrophic Lateral Sclerosis: Drug Targets from Clinical and Pre-Clinical Findings. <i>Current Molecular Pharmacology</i> , 2021, 14, 263-280.	1.5	10
47	Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings. <i>CNS and Neurological Disorders - Drug Targets</i> , 2019, 18, 446-465.	1.4	10
48	Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinson's disease: a Complete Review. , 2017, 1, 001-026.		8
49	Myocardial Preconditioning Potential of Hedgehog Activator Purmorphamine (Smoothed Receptor) Tj ETQq1 1 0.784314 rgBT /Over <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2019, 10, 47-56.	0.4	7
50	Dementia " A Complete Literature Review on Various Mechanisms Involves in Pathogenesis and an Intracerebroventricular Streptozotocin Induced Alzheimer's Disease. , 2012, , .		6
51	Neuroprotective Strategies of Blood-Brain Barrier Penetrant "Forskolin" (AC/cAMP/PK _A /CREB Activator) to Ameliorate Mitochondrial Dysfunctioning in Neurotoxic Experimental Model of Autism. , 0, , .		5
52	Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism. <i>Current Drug Targets</i> , 2021, 22, 1071-1086.	2.1	5
53	Precautionary Ellagic Acid Treatment Ameliorates Chronically Administered Scopolamine Induced Alzheimer's Type Memory and Cognitive Dysfunctions in Rats. <i>Pharmacologia</i> , 2015, 6, 192-212.	0.3	5
54	Activation of SIRT-1 Signalling in the Prevention of Bipolar Disorder and Related Neurocomplications: Target Activators and Influences on Neurological Dysfunctions. <i>Neurotoxicity Research</i> , 2022, 40, 670-686.	2.7	5

#	ARTICLE	IF	CITATIONS
55	Involvement of Phytochemical-Encapsulated Nanoparticlesâ€™ Interaction with Cellular Signalling in the Amelioration of Benign and Malignant Brain Tumours. <i>Molecules</i> , 2022, 27, 3561.	3.8	5
56	Neuroprotective Effect of Chrysophanol as a PI3K/AKT/mTOR Signaling Inhibitor in an Experimental Model of Autologous Blood-induced Intracerebral Hemorrhage. <i>Current Medical Science</i> , 2022, , 1.	1.8	4
57	Possible Therapeutic Interventions in COVID-19 Induced ARDS by Cotinine as an ACE-2 Promoter and AT-1R Blocker. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, e170721189261.	0.8	3
58	Spices, Fruits, Nuts and Vitamins: Preventive Interventions for Myocardial Infarction. <i>Pharmacologia</i> , 2013, 4, 553-570.	0.3	3
59	Renoprotective Effect of Ace Inhibitor-Lisinopril and Heme Oxygenase-1 Inducer-Hemin Combination against Streptozotocin Induced Advanced Diabetic Nephropathy in Rats. <i>Pharmacologia</i> , 2014, 5, 60-75.	0.3	1
60	Forskolin, ameliorates mitochondrial dysfunction in Streptozotocin induced diabetic nephropathy in rats. <i>Asian Journal of Pharmacy and Pharmacology</i> , 2018, 5, 199-206.	0.1	1
61	Role of adenylyl cyclase activator in controlling experimental diabetic nephropathy in rats. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2018, 10, 144-153.	0.8	1
62	Polyphenols Targeting and Influencing Cellular Signaling During Progression and Treatment of Cancer. , 2021, , 95-141.		0
63	Green Nanoparticles: A Hope for Targeted Delivery of Natural Therapeutics for the Management of Glioblastoma Multiforme (GBM). , 2021, , 397-437.		0
64	Current Neuropharmacological Interventions in Autism: Potential Drug Targets from Pre-clinical and Clinical Findings. <i>Current Psychopharmacology</i> , 2021, 10, 98-114.	0.3	0
65	Cellular Signals like MAPK/NF- κ B/m-TOR Mediated Drug Resistance: A Promising Concept in Cancer Research. <i>Pharmacologia</i> , 2013, 4, 414-427.	0.3	0
66	Clinical Therapeutic Strategies to Ameliorate the Mitochondrial ETC Complexes Dysfunctions in Autism: First Time from India. <i>Virology & Immunology Journal</i> , 2017, 1, .	0.1	0
67	Sonic Hedgehog Signaling Activation Promotes Cardioprotective Strategies. <i>Current Signal Transduction Therapy</i> , 2020, 15, 197-204.	0.5	0